“Our donor community is passionate, invigorated and vitally interested in making a unique and lasting impact on breast cancer research,” said Komen interim President and Chief Executive Officer, Ellen Willmott. In HR-positive, HER2-negative MBC, chemotherapy generally is used following progression on endocrine therapy or in women for whom endocrine therapy is not indicated. In HR-positive, HER2-negative MBC, chemotherapy generally is used following progression on endocrine therapy or in women for whom endocrine therapy is not indicated. In the U.S., an estimated 271,000 new cases are diagnosed and approximately 42,000 women will die of the disease each year, making it the second-leading cause of cancer death in women (American Cancer Society). SUSAN G. KOMEN® LAUNCHES ITS FIRST CROWDFUNDING INITIATIVE TO SUPPORT METASTATIC BREAST CANCER RESEARCH, Your Generous Donation, Supported by a Dollar-for-Dollar Match from Odonate Therapeutics™, Will Go toward Advancing the Treatment of Patients Suffering from the Leading Cause of Cancer Deaths in Women Worldwide. Whether helping the community as a whole or donating in honor of or in memory of a loved one, each donation helps sustain our mission to educate the community and fight to end breast cancer. Over the past two decades, only modest survival benefits have been achieved in this patient population; hence, treatment goals emphasize controlling disease-related symptoms, minimizing toxicity and maximizing quality-of-life: “…therapeutic goals for those with advanced disease include disease control, preservation or improvement in quality of life and prolongation of survival, with symptom palliation…”. Individuals and organizations looking to contribute to advancements in metastatic breast cancer research can now do so by participating in Susan G. Komen’s inaugural crowdfunding initiative, launched today in recognition of National Breast Cancer Awareness Month (NBCAM). Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, … In Europe, an estimated 523,000 new cases are diagnosed (World Health Organization) and approximately 138,000 women will die of the disease each year (World Health Organization), making it the leading cause of cancer death in women (World Health Organization). The MSK Ralph Lauren Center provides free, high-quality care and, as of September 2020, has screened more than 200,000 women for breast cancer. Visit komen.org or call 1-877 GO KOMEN. The initial focus of the company is on Tesetaxel, which is currently undergoing clinical testing for breast cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. SAN DIEGO– (BUSINESS WIRE)– Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and … Donors will have the opportunity to hear the researchers’ stories, learn about their work and better understand the impact that each researcher is making or hopes to make in breast cancer research. The company's share price nose … As second-line endocrine therapy in women with HR-positive, HER2-negative disease, fulvestrant plus palbociclib resulted in median PFS of 9.5 months, compared to 4.6 months with fulvestrant alone (Cristofanilli et al., The Lancet 2016;17(4):425-439). Breast cancers generally are categorized by the presence or absence of these receptors. Odonate recently announced positive top-line results from CONTESSA, and full results are scheduled to be presented at the San Antonio Breast Cancer Symposium in December 2020. HR-positive, HER2-negative disease, which represents the majority of all MBC cases, remains an area of high unmet medical need. Tesetaxel currently is the subject of three studies in breast cancer… … Breast Cancer Epidemiology. While sequential monotherapy is appropriate for many patients, chemotherapy combinations are considered useful in patients with high tumor burden, rapidly progressing disease and visceral crisis (the National Comprehensive Cancer Network [NCCN] Guidelines for Invasive Breast Cancer [V1.2021]). Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. The biotech stock plunged more than 50% earlier this week after Odonate reported results from a phase 3 study evaluating tesetaxel in treating patients with metastatic breast cancer. Since its founding in 1982, Komen has funded more than $956 million in research and provided more than $2.1 billion in funding to screening, education, treatment and psychosocial support programs serving millions of people in more than 30 countries worldwide. That promise has become Komen’s promise to all people facing breast cancer. In a presentation at the 2020 San Antonio Breast Cancer Symposium, Odonate Therapeutics (NASDAQ: ODT) announced positive Phase 3 clinical trial data for tesetaxel, its … Susan G. Komen is the world’s largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. HR-positive, HER2-negative disease, which represents the majority of all MBC cases, remains an area of high unmet medical need. Receptors that are assessed in standard clinical practice include the estrogen receptor (ER) and progesterone receptor (PgR), collectively the hormone receptors (HRs), and human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancer and triple-negative breast cancer (TNBC), the latter of which lacks all three receptors, are less common, accounting for approximately 13% and 11% of breast cancers, respectively (Howlader et al., Journal of the National Cancer Institute 2014;106(5):1-8). Odonate Therapeutics (ODT -0.8%) announces positive results from a multinational, multicenter, randomized CONTESSA, Phase 3 trial evaluating lead candidate tesetaxel in metastatic … This suggests that a significant percentage of women are not indicated for endocrine therapy in the advanced setting due to: (i) a short relapse-free interval while on adjuvant endocrine therapy (endocrine resistance); (ii) rapidly progressing disease/visceral crisis; or (iii) endocrine intolerance. Breast cancer is the leading cause of cancer death in women. Chemotherapy should be “…continued until progression of disease as tolerated because it modestly improves overall survival and substantially improves PFS, but this has to be balanced against toxicity and quality of life” (Partridge et al., Journal of Clinical Oncology 2014;32:3307‑3329).​. Odonate has only one drug, an oral version of well-known chemo drugs called taxanes. Therefore, these pharmaceutical agents must be delivered intravenously, typically at an infusion center, and also are formulated with solubilizing agents that are known to cause hypersensitivity reactions. se are typically treated with endocrine therapy (with or without a CDK 4/6 inhibitor), chemotherapy or both. There are several approved chemotherapy agents for the treatment of HER2-negative MBC. The scientists featured in the crowdfunding campaign were chosen through Komen’s rigorous peer review process based on the great promise of their work seeking to improve our understanding of how breast cancer cells metastasize, or spread, to other parts of the body and investigating ways to use the immune system and targeted therapies to prevent this process of metastasis. “Odonate is dedicated to improving outcomes and quality of life for patients living with breast cancer, and we hope our partnership will encourage others to join us in supporting the vital mission of Susan G. Komen.”. Taxanes are one of the most widely used classes of chemotherapy agents in both Europe and the U.S., with more than 2.8 million cycles administered in 2016 (Symphony Health Solutions 2016; IMS Health 2016). DALLAS, TX AND SAN … Odonate and an affiliated partner will match, on a dollar-for-dollar basis, all donations toward this initiative received between October 2, 2017 and December 31, 2017, up to a maximum of $1.5 million. In addition, Odonate will support Komen’s newly-created Clinical Trials Information Helpline, 1-877-GO-KOMEN (1-877-465-6636). Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. SAN DIEGO–(BUSINESS WIRE)–Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced positive top-line results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer … Breast cancer is the second-most common cancer worldwide, with an estimated 2.1 million new cases diagnosed per year (World Health Organization). Your Generous Donation, Supported by a Dollar-for-Dollar Match from Odonate Therapeutics, , Will Go toward Advancing the Treatment of Patients Suffering from the Leading Cause of Cancer Deaths in Women Worldwide, DALLAS, TX AND SAN DIEGO, CA – Oct. 3, 2017. The Company’s initial focus is on the development of tesetaxel, a novel, orally administered chemotherapy belonging to the taxane class. Odonate recently initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer (MBC). Taxanes are an established class of anticancer agents that are broadly used in various cancers, including breast cancer. … Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer SUSAN G. KOMEN® LAUNCHES ITS FIRST CROWDFUNDING INITIATIVE TO SUPPORT METASTATIC BREAST CANCER RESEARCH . Endocrine agents, with or without targeted agents such as a CDK 4/6 inhibitor, are preferred as initial treatment prior to chemotherapy for most patients with HR-positive, HER2-negative MBC (. Connect with us on social at, Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Tesetaxel is an oral chemotherapy drug, which Odonate Therapeutics … Those interested in supporting and learning more about the crowdfunded grantees are encouraged to visit BeMoreThanPink.org. Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026. MSK Center in Harlem Hits Milestone Early detection is essential to lifting breast cancer survival rates. Your gift means we can bring hope to cancer patients. By Christiana Sciaudone. Donations received for this initiative will go further thanks to a matching commitment from Odonate Therapeutics™, a company dedicated to the development of therapeutics that improve and extend the lives of patients with cancer. Learn more about metastatic breast cancer and Odonate Therapeutic’s effective chemotherapy choice Taxanes destroy cancer cells by preventing them from entering mitosis, a process of cell division, and thereby leading to apoptosis, or cell death. Odonate Therapeutics Inc. (ODT), a pharmaceutical company developing drugs that improve and extend the lives of patients with cancer, has completed enrollment in CONTESSA, a … Patients with HR-positive, HER2-negative disease are typically treated with endocrine therapy (with or without a CDK 4/6 inhibitor), chemotherapy or both. Odonate Therapeutics is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Story … While paclitaxel and docetaxel, the first two taxanes approved for the treatment of breast cancer, possess robust antitumor activity, they have low oral bioavailability and low solubility. To learn more, please visit. That promise has become Komen’s promise to all people facing breast cancer. Investing.com -- Odonate Therapeutics (NASDAQ: ODT) sank more than 31% after announcing results from its Contessa Phase 3 study of tesetaxel in breast cancer … Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. Learn more about metastatic breast cancer and Odonate Therapeutic’s effective chemotherapy choice Through this initiative, donors have the opportunity to contribute directly to the pioneering work of four scientists and their teams who are dedicated to making discoveries that will ultimately improve outcomes for patients suffering from metastatic breast cancer. Tesetaxel has several properties … Those interested in supporting and learning more about the crowdfunded grantees are encouraged to visit, Susan G. Komen is the world’s largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. In a presentation at the 2020 San Antonio Breast Cancer Symposium, Odonate Therapeutics (NASDAQ:ODT) announced positive Phase 3 … Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. By Christiana Sciaudone Investing.com -- Odonate Therapeutics (NASDAQ: ODT) sank more than 31% after announcing results from its Contessa Phase 3 study of tesetaxel in breast cancer patients. As of September 30, 2020, Odonate … Metastatic breast cancer is incurable and is responsible for most of the nation’s 41,000 annual breast cancer deaths. Make a donation to the American Cancer Society. Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026. Breast cancer typically is staged (Stage 0-IV) based on the size of the tumor, whether or not the tumor is invasive, whether or not the cancer is in the lymph nodes, and whether or not the cancer has spread (metastasized) to other parts of the body beyond the breast. Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. National Breast Cancer Foundation provides early detection screenings, including mammograms, breast health education, and a supportive community. As initial therapy in post-menopausal women with ER-positive, HER2-negative disease, letrozole plus the recently approved CDK 4/6 inhibitor, palbociclib, resulted in median progression-free survival (PFS) of 24.8 months, compared to 14.5 months with letrozole alone (Finn et al., New England Journal of Medicine 2016;375(20):1925-1936). In a recent analysis of a large patient record database (n=1,272-1,640 in Europe and n=2,225-2,760 in the U.S.), chemotherapy-only regimens were given as the first therapy following a diagnosis of advanced disease 33%-35% of the time in Europe and 34%-42% of the time in the U.S. (, While sequential monotherapy is appropriate for many patients, chemotherapy combinations are considered useful in patients with high tumor burden, rapidly progressing disease and visceral crisis (, No optimal sequence of chemotherapies is known, and choice of individual regimens and agents depends on physician preferences, as well as previous therapies, residual toxic effects, tumor burden and symptoms (, Anxiety, including institutional-triggered side effects, Heightened awareness of life-threatening disease presence, the National Comprehensive Cancer Network [NCCN] Guidelines for Invasive Breast Cancer [V1.2021]. The primary objective is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone in patients with HER2 negative, HR positive LA/MBC … Therefore, treatment that balances efficacy, tolerability and quality of life is preferred. The prognosis for women with metastatic breast cancer (MBC) remains poor; the 5-year survival rate for metastatic disease is about 27% (American Cancer Society), making this an area of continued, high unmet medical need. Nab-paclitaxel, a different formulation of paclitaxel that also is approved for the treatment of breast cancer, has a greatly reduced risk of hypersensitivity reactions, but must still be delivered intravenously. These include: paclitaxel, nab-paclitaxel and docetaxel (taxanes); capecitabine (a fluoropyrimidine); doxorubicin and epirubicin (anthracyclines); gemcitabine (a nucleoside inhibitor); ixabepilone (an epothilone; approved in the U.S.); and eribulin (a non-taxane microtubule dynamics inhibitor). To date, Komen has invested more than $180 million toward metastatic breast cancer research, and more than 41 percent of Komen’s 2017 grants are devoted to metastatic research. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. For breast health or breast cancer information, please call the Breast Care Helpline: 1-877-465-6636 or helpline@komen.org. TESETAXEL. Your Generous Donation, Supported by a Dollar-for-Dollar Match from Odonate Therapeutics ™, Will Go toward Advancing the Treatment of Patients Suffering from the Leading Cause of Cancer Deaths in Women Worldwide. Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, … Connect with us on social at ww5.komen.org/social. Over the past two decades, only modest survival benefits have been achieved in this patient population; hence, treatment goals emphasize controlling disease-related symptoms, minimizing toxicity and maximizing quality-of-life: “…therapeutic goals for those with advanced disease include disease control, preservation or improvement in quality of life and prolongation of survival, with symptom palliation…” (Di Leo A et al., The Breast 2015;24:321‑330). Donate There are a number of ways to support those affected by breast cancer. Therapies that must be given intravenously at an infusion center often are associated withᵃ: Fear of needles and complications associated with venous access; Anxiety, including institutional-triggered side effects such as nausea and vomiting; Heightened awareness of life-threatening disease presence; and, ᵃ Gornas et al, European Journal of Cancer Care 2010;19(1):131-136; Schott et al, BMC Cancer 2011;11:129, Contact Us          Careers          Privacy Notice          Terms of Use, Breast cancer is the second-most common cancer worldwide, with an estimated 2.1 million new cases diagnosed per year (, Breast cancer typically is staged (Stage 0-IV) based on the size of the tumor, whether or not the tumor is invasive, whether or not the cancer is in the lymph nodes, and whether or not the cancer has spread (metastasized) to other parts of the body beyond the breast. Breast cancer is the second-most common cancer worldwide, with an estimated 2.1 million new cases diagnosed per year (World Health Organization).In Europe, an estimated 523,000 new cases are diagnosed (World Health Organization) and approximately 138,000 women will die of the disease each year (World Health Organization), making it the leading cause of cancer … Your Donations During Breast Cancer Awareness Month Help MSK Save Lives. Odonate is addressing breast cancer via novel low toxicity taxane.